Pfizer to seek emergency use authorization for COVID-19 vaccine


Drugmaker Pfizer said on Tuesday it plans to seek emergency use authorization from the Food and Drug Administration for its Covid-19 vaccine in November, once the safety milestones have been reached.Pfizer, one of the leaders in the race to develop a vaccine against COVID-19, said the final trial of its vaccine candidate has now recruited almost all of the 44,000 planned participants worldwide. Nearly 36,000 people had received the second injection of the two-dose vaccine on Monday.

Notably, he expanded the trial’s recruitment to include people as young as 12 as well as people with chronic stable HIV, hepatitis C, and hepatitis B.

Pediatrician on the COVID vaccine, Halloween without danger …


He hopes to know soon whether the vaccine is effective or not in these populations. Pfizer CEO Albert Bourla previously said the company expected to know if his vaccine worked at the end of October.


Please enter your comment!
Please enter your name here